SAHPRA's enforcement action against weight-loss drugs like Ozempic and Mounjaro: What you need to know

GLP-1 drugs - referring to the hormone that regulates blood glucose levels and appetite, used in the global fight against obesity.

FOLLOWING an investigation into South Africa's aesthetics industry, the South African Health Products Regulatory Authority (SAHPRA), and South African Pharmacy Council (SAPC) have launched a significant crackdown on compounded weight-loss drugs, revealing alarming regulatory non-compliance and potential public health risks.

Days after IOL exposed South Africa's unregulated aesthetics industry and the dangers lurking beneath the country's booming beauty economy, a fresh regulatory storm is gathering, this time targeting the exploding market for compounded versions of blockbuster weight-loss drugs like Ozempic and Mounjaro.

The South African Health Products Regulatory Authority (SAHPRA), working alongside the South African Pharmacy Council (SAPC), has executed its most significant enforcement action yet in the GLP-1 space, raiding a Pretoria-based compounding pharmacy and seizing an entire stockpile of unregistered injectable products.

The raid has ignited a fiery legal dispute, and experts warn the crackdown signals the beginning of the end for South Africa's largely unregulated compounded weight-loss drug market.